There are several good reasons why hospitals and cancer centers would want to use central institutional review boards (IRBs) to supplement their often overburdened local boards that are charged with overseeing research involving human subjects. What's more, several national agencies support central IRBs: The U.S. Food and Drug Administration issued a draft guidance in March to help increase awareness of central IRBs, the Offi ce for Human Research Protections (OHRP) looks favorably on them, and the American Society of Clinical Oncology offi cially endorses their use. So does the National Cancer Institute, which has established two central IRBs for institutions participating in its phase III cooperative group trials.
Centralized review, according to representatives from all of these organizations, can be more effi cient and more effective in protecting clinical trial participants because it reduces the burdens on local IRBs, eliminates duplication of effort, and can bring to bear expertise that may not be available at the local level.
Nevertheless 
Increase in Trials
But in the 1990s, clinical trials proliferated and IRB workloads increased dramatically. Multicenter trials became more common, and IRBs at dozens of institutions were reviewing the same protocols. Staffi ng did not keep pace, and the review process slowed down, Prentice said.
In the meantime, trials sponsored by pharmaceutical companies were increasing in number and moving away from academic centers and into the private sector. That created a need for IRBs that private-practice physicians could use. One result was the growth of independent or "commercial" IRBs that provide reviews for a fee.
At fi rst there was a tendency to suspect independent IRBs of bias in favor of industry sponsors, Prentice said. "But there is no longer that prejudice," he said. "It is clear that many independent IRBs are better than academic IRBs." In fact, some now argue that local IRBs are the ones that may be biased. The Consortium to Examine Clinical Research Ethics, a group established in 2002 under the auspices of Duke University Medical Center, points out that local IRBs can have an inherent confl ict of interest because the IRBs are funded by the same institution that conducts and oversees the research under review. In an editorial that appeared in the Annals of Internal Medicine a year ago, Ezekiel Emmanuel, M.D., chief of clinical bioethics at the National Institutes of Health, and other members of the consortium recommended that central IRB review be required for multisite trials.
The SACHRP took up the central versus local IRB issue at its meeting last October, and the panel agreed to hold a national workshop-which is now sched uled for this fall and will be sponsored by OHRP, ASCO, and the Association of American Medical Colleges-to clarify the value of centralized review and understand barriers to its use. Encouraging centralized review also appears to be one goal of the FDA's draft guidance. "What we are trying to do is get people to think about this possibility," said Bonnie Lee, associate director for human subjects protection policy at the
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FDA. "This might be a way to increase both effi ciency and effectiveness of human research protections." are our values, that we are not merely a deputy sheriff to FDA," he said in an interview. With central review, "you lose a sense of a community of compliance, the ability to infl uence people within the institution," he said.
Barriers to Use
Nevertheless, central review can be practical, Levine acknowledged, especially for the multisite trials common in cancer research. "The oncologists have a point," he said.
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